Bioretec Ltd. Achieves CE Mark Approval
Bioretec Ltd., an innovative leader in absorbable orthopedic implants, reached a significant milestone by successfully obtaining CE mark approval for its RemeOs™ Trauma Screw product range. This pivotal approval allows the company to commercialize its products throughout the European Union and in other non-European countries that recognize CE mark authorization.
Comprehensive Approval for Trauma Screws
The CE mark approval covers a wide array of designs, encompassing both cannulated and non-cannulated options, with sizes varying from diameters of 2.0 mm up to 4.0 mm and lengths from 8 mm to 50 mm. This enhancement ensures that the screws can be utilized for various indications, including fracture and malalignment fixations in adult and pediatric patients, except for the hand and forefoot regions.
Expert Commentary from Bioretec's CEO
Alan Donze, the CEO of Bioretec, expressed enthusiasm regarding the extensive approval. He stated, "We are extremely pleased that the EU market approval includes all designs and a vast number of indications. This milestone enables us to immediately provide RemeOs™ Trauma Screws to numerous patients. Additionally, it opens pathways for market entry into other countries that honor the CE mark, allowing us to gather real-world clinical evidence essential for expanding indications in the U.S., where our current approval is limited."
RemeOs™ Product Line Details
The RemeOs™ product line consists of a selection of implants, notably including RemeOs FT cannulated, RemeOs FL cannulated, RemeOs FC cannulated, and RemeOs LAG Solid. These products represent a significant advancement in orthopedic treatment, featuring biodegradable materials designed to enhance surgical outcomes and promote better healing.
Innovative Approach to Orthopedic Implants
Bioretec stands at the forefront of developing biodegradable orthopedic implants that facilitate healing by being absorbed and replaced by the bone. This approach eliminates the need for subsequent removal surgeries, streamlining the recovery process for patients. Moreover, these advancements align with enhancing value-based healthcare targets, focusing on delivering improved outcomes for patients while optimizing healthcare resources.
Expansion Opportunities in Global Markets
Bioretec is strategically positioning itself to tap into the expansive global orthopedic trauma and spine market, which is valued at over USD 9 billion. The recent approvals pave the way for the introduction of RemeOs™ products in various regions, emphasizing Bioretec's commitment to advancing surgical bone fracture treatment and becoming a key player in the orthopedic sector.
About Bioretec Ltd.
Bioretec, a Finnish medical device company, is dedicated to pioneering the use of biodegradable materials in orthopedic implants. With a unique understanding of the biological interface of active implants, Bioretec aims to enhance bone growth and accelerate the healing process following surgical procedures. Their innovative products are currently utilized in approximately 40 countries worldwide.
For further inquiries, please contact:
Alan Donze, CEO, +1 619 977 5285
Johanna Salko, CFO, +358 40 754 8172
Frequently Asked Questions
What is the significance of the CE mark approval for Bioretec?
The CE mark approval is crucial as it allows Bioretec to commercialize its RemeOs™ Trauma Screws in Europe and other countries recognizing CE compliance, enhancing the company's market reach.
What types of implants are included in the RemeOs™ product line?
The RemeOs™ product line includes various cannulated and non-cannulated trauma screws, featuring different sizes and designs tailored for diverse surgical applications.
How do Bioretec's implants improve patient outcomes?
Bioretec's implants are designed to be absorbed and replaced by bone, eliminating the need for removal surgeries and promoting more efficient healing processes after orthopedic surgery.
What markets does Bioretec aim to penetrate with its products?
Bioretec is focusing on entering the global orthopedic trauma and spine market, which is projected to exceed USD 9 billion, to expand its influence and product offerings.
Who can be contacted for more information about Bioretec?
Alan Donze (CEO) and Johanna Salko (CFO) are available for inquiries regarding Bioretec's products and corporate operations.
